BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/28/2014 2:00:00 PM | Browse: 650 | Download: 738
Publication Name World Journal of Gastroenterology
Manuscript ID 8307
Country/Territory Italy
Received
2013-12-25 09:08
Peer-Review Started
2013-12-25 15:05
To Make the First Decision
2014-02-14 12:54
Return for Revision
2014-02-19 12:29
Revised
2014-02-25 04:50
Second Decision
2014-05-29 19:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-29 19:52
Articles in Press
2014-05-29 20:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-08-13 17:23
Publish the Manuscript Online
2014-08-29 11:57
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Hematology
Manuscript Type Topic Highlights
Article Title Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment
Manuscript Source Invited Manuscript
All Author List Carlo Visco and Silvia Finotto
Funding Agency and Grant Number
Funding Agency Grant Number
AViLL/AIL (Associazione Vicentina per le Leucemie, i Linfomi e il Mieloma/Associazione Italiana Leucemie) (Vicenza, Italy)
Hematology Project Foundation (HPF, Fondazione Progetto Ematologia, Vicenza, Italy)
Corresponding Author Correspondence to: Carlo Visco, MD, Department of Hematology and Cell Therapy, San Bortolo Hospital, Ospedale San Bortolo, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com
Key Words Hepatitis C virus; Non-Hodgkin lymphoma; Liver; Toxicity; Diffuse large B-cell lymphoma; Rituximab; Cyclophosphamide; Hydroxydaunorubicin; Vincristine; Prednisolone; Immuno-chemotherapy; Antiviral treatment
Core Tip Patients with hepatitis C virus-positive diffuse large B-cell lymphoma should be managed in a multidisciplinary setting. Initial evaluation of liver status and comorbidities is essential to establish if the patient is candidate to curative approaches. Unless contraindicated by adverse clinical conditions, patients should be treated with standard immuno-chemotherapy. Concomitant hepatitis B virus infection and liver failure or cirrhosis confer a significantly higher risk of viral reactivation or therapy related complications. These patients should be managed cautiously and treated with less intense approaches at least for the initial cycles. Antiviral treatment should be considered after the end of immuno-chemotherapy, when lymphoma remission has been achieved.
Publish Date 2014-08-29 11:57
Citation Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. World J Gastroenterol 2014; 20(32): 11054-11061
URL http://www.wjgnet.com/1007-9327/full/v20/i32/11054.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i32.11054
Full Article (PDF) WJG-20-11054.pdf
Full Article (Word) WJG-20-11054.doc
Manuscript File 8307-Review.docx
Answering Reviewers 8307-Answering reviewers.pdf
Copyright License Agreement 8307-Copyright assignment.pdf
Peer-review Report 8307-Peer reviews.pdf
Scientific Misconduct Check 8307-CrossCheck.jpg
Scientific Editor Work List 8307-Scientific editor work list.pdf